Choose the stock you wish to monitor with a price target
Recently viewedPrice
↑↓ to move↵ to choose
Back to Note
Company Overview
Business Description
Sector
Health Care
Industry
Life Sciences Tools & Services
Headquarters
United States of AmericaUS
Employees
11 000
IPO date
Jul 6, 1965
Revvity makes tools and tests used in laboratories that study biology and diagnose disease. Its products include laboratory instruments, reagents, assay kits, software, and related services that help customers measure biological signals, run genetic and biochemical tests, and analyze results. The company serves drug developers, biotech and academic research labs, and clinical and public health laboratories.
The company makes money in a few main ways: it sells instruments and software systems upfront, and it also sells the consumable chemicals, test kits, and service contracts that customers keep buying after the equipment is installed. That gives Revvity a mix of one-time sales and recurring revenue tied to the ongoing use of its platforms. In diagnostics, its products help labs detect and monitor disease; in research, they help scientists discover and develop new medicines.
What makes Revvity’s business model distinct is that it sits in the middle of the lab workflow. It does not just sell standalone equipment; it sells the tools, tests, and support that labs use repeatedly to generate data and make decisions. That makes the company an important supplier to both healthcare testing and life sciences research, where customers care about accuracy, reliability, and easy-to-run workflows.
This segment sells instruments, reagents, software, and lab services that help scientists study biology, chemistry, and disease in research labs. It supports drug discovery, genomics, and other laboratory testing workflo...
Customers and revenue model
Diagnostics
This segment provides tests, instruments, reagents, and automation systems used to screen patients, confirm diagnoses, and support prenatal, newborn, and disease testing in clinical labs.
Customers and revenue model
Management
Dr. Prahlad R. Singh Ph.D.
CEO, President & Director
Biography unavailable
Mr. Maxwell Krakowiak
Senior VP & CFO
Biography unavailable
Mr. Tajinder S. Vohra
Senior Vice President of Global Operations
Biography unavailable
Mr. Joel S. Goldberg
Senior VP of Administration, General Counsel & Secretary
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.